TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: STAR: Solitaire FR Thrombectomy for Acute Revascularisation
Brief Summary: The objective of this study was to obtain prospective clinical data on the safety and efficacy of the Solitaire™ FR device for patients diagnosed with acute ischemic stroke.


Options:
A: Arm Label: IV t-PA with Solitaire™ revascularization device; Type: EXPERIMENTAL; Interventions: Device: Solitaire revascularization device | Arm Label: IV t-PA; Type: ACTIVE_COMPARATOR; Interventions: Drug: Intravenous (IV) recombinant human tissue plasminogen activator (rtPA) | Intervention Type: DRUG; Name: Intravenous (IV) recombinant human tissue plasminogen activator (rtPA); Assigned to Arm(s): IV t-PA | Intervention Type: DEVICE; Name: Solitaire revascularization device; Assigned to Arm(s): IV t-PA with Solitaire™ revascularization device
B: Arm Label: Solitaire™ FR device; Type: N/A; Interventions: Device: Solitaire™ FR device | Intervention Type: DEVICE; Name: Solitaire™ FR device; Assigned to Arm(s): Solitaire™ FR device
C: Arm Label: intravenous (IV) rt-PA alone; Type: ACTIVE_COMPARATOR; Interventions: Drug: IV rt-PA alone | Arm Label: Endovascular therapy; Type: EXPERIMENTAL; Interventions: Drug: IV rt-PA alone, Other: endovascular therapy | Intervention Type: DRUG; Name: IV rt-PA alone; Assigned to Arm(s): Endovascular therapy, intravenous (IV) rt-PA alone | Intervention Type: OTHER; Name: endovascular therapy; Assigned to Arm(s): Endovascular therapy
D: Arm Label: Intra-arterial Clot Retrieval after iv tPA; Type: EXPERIMENTAL; Interventions: Device: Intra-arterial Clot Retrieval with Solitaire device | Arm Label: Standard care iv tPA; Type: ACTIVE_COMPARATOR; Interventions: Genetic: intravenous tissue plasminogen activator (tPA) | Intervention Type: DEVICE; Name: Intra-arterial Clot Retrieval with Solitaire device; Assigned to Arm(s): Intra-arterial Clot Retrieval after iv tPA | Intervention Type: GENETIC; Name: intravenous tissue plasminogen activator (tPA); Assigned to Arm(s): Standard care iv tPA

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Multicenter, Randomized, Double-blind, Placebo-Controlled Withdrawal Study to Evaluate the Safety, Tolerability, and Efficacy of Milnacipran in Pediatric Patients With Primary Fibromyalgia
Brief Summary: The purpose of this study is to evaluate the safety, tolerability, efficacy, and pharmacokinetics of milnacipran in pediatric patients aged 13 to 17 years with primary fibromyalgia.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Minalcipran; Type: EXPERIMENTAL; Interventions: Drug: milnacipran | Intervention Type: DRUG; Name: milnacipran; Assigned to Arm(s): Minalcipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Milnacipran; Type: EXPERIMENTAL; Interventions: Drug: Milnacipran | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): Milnacipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Patients taking the drug Milnacipran; Type: ACTIVE_COMPARATOR; Interventions: Drug: Milnacipran | Arm Label: Patients taking the placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Milnacipran; Assigned to Arm(s): Patients taking the drug Milnacipran | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Patients taking the placebo
D: Arm Label: Minalcipran 100 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Arm Label: Minalcipran 150 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Arm Label: Minalcipran 200 mg; Type: EXPERIMENTAL; Interventions: Drug: milnacipran, Drug: Placebo | Intervention Type: DRUG; Name: milnacipran; Assigned to Arm(s): Minalcipran 100 mg, Minalcipran 150 mg, Minalcipran 200 mg | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Minalcipran 100 mg, Minalcipran 150 mg, Minalcipran 200 mg

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Feasibility Study of the PneumRx, Inc. Lung Volume Reduction Coil for the Treatment of Emphysema
Brief Summary: This is a multicenter single arm open label study. The primary objective is to evaluate the safety and effectiveness of the Lung Volume Reduction Coil (LVRC) for the treatment of patients with emphysema in multiple centers.


Options:
A: Arm Label: bilateral; Type: ACTIVE_COMPARATOR; Interventions: Device: IBV Implantation | Arm Label: unilateral; Type: ACTIVE_COMPARATOR; Interventions: Device: IBV Implantation | Intervention Type: DEVICE; Name: IBV Implantation; Assigned to Arm(s): unilateral | Intervention Type: DEVICE; Name: IBV Implantation; Assigned to Arm(s): bilateral
B: Arm Label: Lung Volume Reduction Coil (LVRC); Type: EXPERIMENTAL; Interventions: Device: Lung Volume Reduction Coil (LVRC) (PneumRx's) | Intervention Type: DEVICE; Name: Lung Volume Reduction Coil (LVRC) (PneumRx's); Assigned to Arm(s): Lung Volume Reduction Coil (LVRC)
C: Arm Label: Medical management; Type: NO_INTERVENTION; Interventions: Device: IBV Valve | Intervention Type: DEVICE; Name: IBV Valve; Assigned to Arm(s): Medical management
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: IBV® Valve System | Arm Label: 2; Type: SHAM_COMPARATOR; Interventions: Device: IBV® Valve System | Intervention Type: DEVICE; Name: IBV® Valve System; Assigned to Arm(s): 1, 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Roflumilast on Exacerbation Rate in Patients With COPD Treated With Fixed Combinations of LABA and ICS. A 52-week, Randomised Double-blind Trial With Roflumilast 500 µg Versus Placebo. The REACT Trial
Brief Summary: The objective of the REACT trial is to investigate the effect of roflumilast 500 μg tablets once daily versus placebo on exacerbation rate and pulmonary function in COPD patients who are concomitantly treated with a fixed combination of long-acting β2-agonists (LABA) and inhaled glucocorticosteroids (ICS). In addition, data on safety and tolerability of roflumilast will be obtained. An additional objective is to further characterize the population pharmacokinetic profile of roflumilast and roflumilast N oxide and to further characterize their pharmacokinetics/pharmacodynamics (PK/PD) relationship in terms of efficacy and relevant safety aspects.

Patients to be included are required to have severe COPD associated with chronic bronchitis and a history of frequent exacerbations and must be concomitantly treated with a fixed combination of LABA and ICS. Two parallel treatment arms (roflumilast 500 μg once daily and placebo) are included.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Roflumilast | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2
B: Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): N/A
C: Intervention Type: DRUG; Name: Salmeterol 50mcg/ Fluticasone Propionate 500mcg; Assigned to Arm(s): N/A
D: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Roflumilast on Exacerbation Rate in Patients With COPD Treated With Fixed Combinations of LABA and ICS. A 52-week, Randomised Double-blind Trial With Roflumilast 500 µg Versus Placebo. The REACT Trial
Brief Summary: The objective of the REACT trial is to investigate the effect of roflumilast 500 μg tablets once daily versus placebo on exacerbation rate and pulmonary function in COPD patients who are concomitantly treated with a fixed combination of long-acting β2-agonists (LABA) and inhaled glucocorticosteroids (ICS). In addition, data on safety and tolerability of roflumilast will be obtained. An additional objective is to further characterize the population pharmacokinetic profile of roflumilast and roflumilast N oxide and to further characterize their pharmacokinetics/pharmacodynamics (PK/PD) relationship in terms of efficacy and relevant safety aspects.

Patients to be included are required to have severe COPD associated with chronic bronchitis and a history of frequent exacerbations and must be concomitantly treated with a fixed combination of LABA and ICS. Two parallel treatment arms (roflumilast 500 μg once daily and placebo) are included.


Options:
A: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): N/A
C: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Daliresp; Type: ACTIVE_COMPARATOR; Interventions: Drug: roflumilast | Intervention Type: DRUG; Name: roflumilast; Assigned to Arm(s): Daliresp | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Roflumilast on Exacerbation Rate in Patients With COPD Treated With Fixed Combinations of LABA and ICS. A 52-week, Randomised Double-blind Trial With Roflumilast 500 µg Versus Placebo. The REACT Trial
Brief Summary: The objective of the REACT trial is to investigate the effect of roflumilast 500 μg tablets once daily versus placebo on exacerbation rate and pulmonary function in COPD patients who are concomitantly treated with a fixed combination of long-acting β2-agonists (LABA) and inhaled glucocorticosteroids (ICS). In addition, data on safety and tolerability of roflumilast will be obtained. An additional objective is to further characterize the population pharmacokinetic profile of roflumilast and roflumilast N oxide and to further characterize their pharmacokinetics/pharmacodynamics (PK/PD) relationship in terms of efficacy and relevant safety aspects.

Patients to be included are required to have severe COPD associated with chronic bronchitis and a history of frequent exacerbations and must be concomitantly treated with a fixed combination of LABA and ICS. Two parallel treatment arms (roflumilast 500 μg once daily and placebo) are included.


Options:
A: Arm Label: Indacaterol; Type: EXPERIMENTAL; Interventions: Drug: Indacaterol 150 µg | Arm Label: Tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium | Intervention Type: DRUG; Name: Indacaterol 150 µg; Assigned to Arm(s): Indacaterol | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium
B: Arm Label: Roflumilast; Type: ACTIVE_COMPARATOR; Interventions: Drug: Roflumilast | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Roflumilast; Assigned to Arm(s): Roflumilast | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Relovair; Type: EXPERIMENTAL; Interventions: Drug: fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI) | Arm Label: Tiotropium; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tiotropium | Intervention Type: DRUG; Name: fluticasone furoate (FF, GW685698)/vilanterol (VI, GW642444) 100/25 mcg Novel Dry Powder Inhaler (NDPI); Assigned to Arm(s): Relovair | Intervention Type: DRUG; Name: Tiotropium; Assigned to Arm(s): Tiotropium
D: Arm Label: QVA149; Type: EXPERIMENTAL; Interventions: Drug: QVA149 | Arm Label: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS); Type: ACTIVE_COMPARATOR; Interventions: Drug: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS) | Intervention Type: DRUG; Name: QVA149; Assigned to Arm(s): QVA149 | Intervention Type: DRUG; Name: Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS); Assigned to Arm(s): Long acting B2 agonist (LABA) and inhaled corticosteroid (ICS)

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Tailored Youth Drug Intervention In Primary Care
Brief Summary: This study examines the impact of tailored computer-delivered and therapist-delivered brief motivations prevention/interventions both for adolescents who have not initiated marijuana use (prevention), and those who use marijuana (intervention). Key moderators of prevention/intervention effectiveness will be examined, including behavioral intentions, self-efficacy, stage of change, school involvement, susceptibility to peer pressure, and potential health consequences such as STD/HIV risk behaviors. This project will provide the critical first step toward the development and implementation of marijuana use prevention/intervention programs that have the potential to be delivered to a large segment of youth who seek care in our nation's primary care settings.


Options:
A: Arm Label: 1) MI/Family Check-Up; Type: EXPERIMENTAL; Interventions: Behavioral: MI/Family Check-up | Arm Label: 2) MI only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: MI only | Intervention Type: BEHAVIORAL; Name: MI/Family Check-up; Assigned to Arm(s): 1) MI/Family Check-Up | Intervention Type: BEHAVIORAL; Name: MI only; Assigned to Arm(s): 2) MI only
B: Arm Label: Information only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Information only | Arm Label: sexual risk reduction intervention; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Sexual risk reduction intervention | Arm Label: SRRI+ETOH; Type: EXPERIMENTAL; Interventions: Behavioral: sexual risk reduction + alcohol risk reduction component | Intervention Type: BEHAVIORAL; Name: Information only; Assigned to Arm(s): Information only | Intervention Type: BEHAVIORAL; Name: Sexual risk reduction intervention; Assigned to Arm(s): sexual risk reduction intervention | Intervention Type: BEHAVIORAL; Name: sexual risk reduction + alcohol risk reduction component; Assigned to Arm(s): SRRI+ETOH
C: Arm Label: BMI-T; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: BMI-T | Arm Label: BMI-C; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: BMI-C | Arm Label: DPB; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: BMI-T; Assigned to Arm(s): BMI-T | Intervention Type: BEHAVIORAL; Name: BMI-C; Assigned to Arm(s): BMI-C
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Adapted Motivational Interviewing & Skills Training | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Adapted Motivational Interviewing & Skills Training | Arm Label: 3; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Adapted Motivational Interviewing & Skills Training; Assigned to Arm(s): 1, 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Evaluation of Hydrocodone/Acetaminophen for Pain Control in First Trimester Surgical Abortion
Brief Summary: The purpose of this study is to determine whether preoperatively administered hydrocodone/acetaminophen (HC/APAP) reduces pain during a first trimester surgical abortion.


Options:
A: Arm Label: Nitrous oxide administration; Type: EXPERIMENTAL; Interventions: Other: Nitrous oxide administration | Arm Label: Standard care group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Nitrous oxide administration; Assigned to Arm(s): Nitrous oxide administration
B: Arm Label: Hydrocodone/acetaminophen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Hydrocodone/acetaminophen, Drug: Ibuprofen, Drug: Lorazepam, Drug: Lidocaine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Ibuprofen, Drug: Lorazepam, Drug: Lidocaine | Intervention Type: DRUG; Name: Hydrocodone/acetaminophen; Assigned to Arm(s): Hydrocodone/acetaminophen | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Ibuprofen; Assigned to Arm(s): Hydrocodone/acetaminophen, Placebo | Intervention Type: DRUG; Name: Lorazepam; Assigned to Arm(s): Hydrocodone/acetaminophen, Placebo | Intervention Type: DRUG; Name: Lidocaine; Assigned to Arm(s): Hydrocodone/acetaminophen, Placebo
C: Arm Label: Gabapentin group; Type: EXPERIMENTAL; Interventions: Drug: Gabapentin | Arm Label: Placebo group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): Gabapentin group | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo group
D: Arm Label: Group 1: Placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Group 2: Gabapentin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gabapentin | Intervention Type: DRUG; Name: Gabapentin; Assigned to Arm(s): Group 2: Gabapentin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Group 1: Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis
Brief Summary: The purpose of the study is to evaluate the safety and efficacy of laser atherectomy with balloon angioplasty compared to balloon angioplasty alone in the treatment of above the knee peripheral artery in-stent restenosis.


Options:
A: Arm Label: Laser atherectomy and PTA; Type: EXPERIMENTAL; Interventions: Device: Turbo Elite Laser and Turbo Tandem Laser Guide Catheters | Arm Label: Balloon angioplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Balloon angioplasty | Intervention Type: DEVICE; Name: Turbo Elite Laser and Turbo Tandem Laser Guide Catheters; Assigned to Arm(s): Laser atherectomy and PTA | Intervention Type: PROCEDURE; Name: Balloon angioplasty; Assigned to Arm(s): Balloon angioplasty
B: Arm Label: Drug-eluting balloon; Type: EXPERIMENTAL; Interventions: Device: Cotavance Drug-Eluting Balloon | Arm Label: Plaque excision + drug-eluting balloon; Type: EXPERIMENTAL; Interventions: Device: TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon | Arm Label: Severely Ca++ Group; Type: EXPERIMENTAL; Interventions: Device: TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon | Intervention Type: DEVICE; Name: Cotavance Drug-Eluting Balloon; Assigned to Arm(s): Drug-eluting balloon | Intervention Type: DEVICE; Name: TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon; Assigned to Arm(s): Plaque excision + drug-eluting balloon | Intervention Type: DEVICE; Name: TurboHawk/SilverHawk + Cotavance Drug-Eluting Balloon; Assigned to Arm(s): Severely Ca++ Group
C: Arm Label: Stenting; Type: ACTIVE_COMPARATOR; Interventions: Device: Stenting (Smart Stent) | Arm Label: Stenting after PEB; Type: EXPERIMENTAL; Interventions: Device: Stenting (Smart Stent), Device: Stenting after PEB (Smart Stent, Invatec) | Arm Label: Atherectomy; Type: EXPERIMENTAL; Interventions: Procedure: Atherectomy (SilverHawk device) | Intervention Type: DEVICE; Name: Stenting (Smart Stent); Assigned to Arm(s): Stenting, Stenting after PEB | Intervention Type: DEVICE; Name: Stenting after PEB (Smart Stent, Invatec); Assigned to Arm(s): Stenting after PEB | Intervention Type: PROCEDURE; Name: Atherectomy (SilverHawk device); Assigned to Arm(s): Atherectomy
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Device: PTA with placement of paclitaxel-eluting stent | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Device: PTA | Intervention Type: DEVICE; Name: PTA with placement of paclitaxel-eluting stent; Assigned to Arm(s): 1 | Intervention Type: DEVICE; Name: PTA; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: EXCImer Laser Randomized Controlled Study for Treatment of FemoropopliTEal In-Stent Restenosis
Brief Summary: The purpose of the study is to evaluate the safety and efficacy of laser atherectomy with balloon angioplasty compared to balloon angioplasty alone in the treatment of above the knee peripheral artery in-stent restenosis.


Options:
A: Arm Label: DEB; Type: N/A; Interventions: Device: DEB | Arm Label: conventional PTA; Type: N/A; Interventions: Device: POBA | Intervention Type: DEVICE; Name: DEB; Assigned to Arm(s): DEB | Intervention Type: DEVICE; Name: POBA; Assigned to Arm(s): conventional PTA
B: Arm Label: Endoprosthesis; Type: EXPERIMENTAL; Interventions: Device: GORE VIABAHN® Endoprosthesis | Arm Label: Plain old balloon angioplasty; Type: ACTIVE_COMPARATOR; Interventions: Device: Plain old balloon angioplasty | Intervention Type: DEVICE; Name: GORE VIABAHN® Endoprosthesis; Assigned to Arm(s): Endoprosthesis | Intervention Type: DEVICE; Name: Plain old balloon angioplasty; Assigned to Arm(s): Plain old balloon angioplasty
C: Arm Label: Laser atherectomy and PTA; Type: EXPERIMENTAL; Interventions: Device: Turbo Elite Laser and Turbo Tandem Laser Guide Catheters | Arm Label: Balloon angioplasty; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Balloon angioplasty | Intervention Type: DEVICE; Name: Turbo Elite Laser and Turbo Tandem Laser Guide Catheters; Assigned to Arm(s): Laser atherectomy and PTA | Intervention Type: PROCEDURE; Name: Balloon angioplasty; Assigned to Arm(s): Balloon angioplasty
D: Arm Label: Paclitaxel eluting balloon; Type: ACTIVE_COMPARATOR; Interventions: Device: drug eluting balloon angioplasty | Arm Label: Standard balloon angioplasty; Type: ACTIVE_COMPARATOR; Interventions: Device: standard balloon angioplasty | Intervention Type: DEVICE; Name: drug eluting balloon angioplasty; Assigned to Arm(s): Paclitaxel eluting balloon | Intervention Type: DEVICE; Name: standard balloon angioplasty; Assigned to Arm(s): Standard balloon angioplasty

Answer: C